S-3 GROUP

Lobbying for ALKERMES, INC. · Global biopharmaceutical company specializing in innovative treatments

Filing 2nd Quarter - Report

2nd Quarter (Apr 1 - June 30) 2025 · District of Columbia · House · Senate · $90,000.00 income · posted Jul 18, 2025

Lobbying activity 1

Alcohol and Drug Abuse

Issues related to legislation and policies that support treatment for alcohol and opioid dependency at SAMSHA, VA and DOJ

Source: federal Lobbying Disclosure Act filing. Bills are parsed from the activity descriptions.